TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE 25 May, 2022 Read More »
TikoMed and IQVIA announce a strategic collaboration for the development of TIKOMED’s lead drug platform candidate ILB® 5 May, 2022 Read More »
TIKOMED’S ILB® attenuates clinical symptoms and serum biomarkers of oxidative/nitrosative stress and mitochondrial dysfunction in patients with ALS in data published by the Journal of Personalized Medicine 16 August, 2021 Read More »
First patient treated in TIKOMED’s Phase II study of clinical islet transplantation in patients with brittle diabetes 12 February, 2021 Read More »
TIKOMED’S ILB® resolves inflammatory scarring and promotes functional tissue repair in data published in npj Regenerative Medicine 26 January, 2021 Read More »
Update regarding our Amyotrophic Lateral Sclerosis (ALS) study conducted at Sahlgrenska University Hospital in Gothenburg, Sweden 9 October, 2020 Read More »
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants 14 September, 2020 Read More »
TIKOMED granted Orphan Medicinal Drug Designation for ILB® for the treatment of amyotrophic lateral sclerosis by the European Commission 28 August, 2020 Read More »
TIKOMED secures 5 M € funding for the clinical development of ILB™ and IBSOLVMIR® 13 March, 2020 Read More »
Locust Walk appointed Strategic and Business Development Advisor for the licensing process of ILB™ 9 March, 2020 Read More »
Information regarding our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital 14 June, 2019 Read More »
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency 30 November, 2018 Read More »
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission 20 August, 2018 Read More »
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board. 5 July, 2018 Read More »
